A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Standard

A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. / Paulsen, G; Egner, I M; Drange, M; Langberg, Henning; Benestad, H B; Fjeld, J G; Hallén, J; Raastad, T.

I: Scandinavian Journal of Medicine & Science in Sports, Bind 20, Nr. 1, 2010, s. e195-207.

Publikation: Bidrag til tidsskriftTidsskriftartikelfagfællebedømt

Harvard

Paulsen, G, Egner, IM, Drange, M, Langberg, H, Benestad, HB, Fjeld, JG, Hallén, J & Raastad, T 2010, 'A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise', Scandinavian Journal of Medicine & Science in Sports, bind 20, nr. 1, s. e195-207. https://doi.org/10.1111/j.1600-0838.2009.00947.x

APA

Paulsen, G., Egner, I. M., Drange, M., Langberg, H., Benestad, H. B., Fjeld, J. G., Hallén, J., & Raastad, T. (2010). A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. Scandinavian Journal of Medicine & Science in Sports, 20(1), e195-207. https://doi.org/10.1111/j.1600-0838.2009.00947.x

Vancouver

Paulsen G, Egner IM, Drange M, Langberg H, Benestad HB, Fjeld JG o.a. A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. Scandinavian Journal of Medicine & Science in Sports. 2010;20(1):e195-207. https://doi.org/10.1111/j.1600-0838.2009.00947.x

Author

Paulsen, G ; Egner, I M ; Drange, M ; Langberg, Henning ; Benestad, H B ; Fjeld, J G ; Hallén, J ; Raastad, T. / A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise. I: Scandinavian Journal of Medicine & Science in Sports. 2010 ; Bind 20, Nr. 1. s. e195-207.

Bibtex

@article{3914a1a74a3f49a6b2189634e9c845fe,
title = "A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise",
abstract = "The aim of this study was to investigate the effect of a cyclooxygenase (COX)-2 inhibitor on the recovery of muscle function, inflammation, regeneration after, and adaptation to, unaccustomed eccentric exercise. Thirty-three young males and females participated in a double-blind, placebo-controlled experiment. Seventy unilateral, voluntary, maximal eccentric actions with the elbow flexors were performed twice (bouts 1 and 2) with the same arm, separated by 3 weeks. The test group participants were administered 400 mg/day of celecoxib for 9 days after bout 1. After both bouts 1 and 2, concentric and isometric force-generating capacity was immediately reduced (approximately 40-50%), followed by the later appearance of muscle soreness and increased serum creatine kinase levels. Radiolabelled autologous leukocytes (detected by scintigraphy) and monocytes/macrophages (histology) accumulated in the exercised muscles, simultaneously with increased satellite cell activity. These responses were reduced and recovery was faster after bout 2 than 1, demonstrating a repeated-bout effect. No differences between the celecoxib and placebo groups were detected, except for muscle soreness, which was attenuated by celecoxib. In summary, celecoxib, a COX-2 inhibitor, did not detectably affect recovery of muscle function or markers of inflammation and regeneration after unaccustomed eccentric exercise, nor did the drug influence the repeated-bout effect. However, it alleviated muscle soreness.",
keywords = "Adaptation, Physiological, Adult, Arm, Cyclooxygenase 2 Inhibitors, Dinoprostone, Double-Blind Method, Exercise, Female, Humans, Immunohistochemistry, Isometric Contraction, Leukocytes, Male, Microdialysis, Muscle Contraction, Muscle, Skeletal, Pain, Pyrazoles, Recovery of Function, Satellite Cells, Skeletal Muscle, Sulfonamides, Young Adult",
author = "G Paulsen and Egner, {I M} and M Drange and Henning Langberg and Benestad, {H B} and Fjeld, {J G} and J Hall{\'e}n and T Raastad",
year = "2010",
doi = "10.1111/j.1600-0838.2009.00947.x",
language = "English",
volume = "20",
pages = "e195--207",
journal = "Scandinavian Journal of Medicine & Science in Sports",
issn = "0905-7188",
publisher = "Wiley-Blackwell",
number = "1",

}

RIS

TY - JOUR

T1 - A COX-2 inhibitor reduces muscle soreness, but does not influence recovery and adaptation after eccentric exercise

AU - Paulsen, G

AU - Egner, I M

AU - Drange, M

AU - Langberg, Henning

AU - Benestad, H B

AU - Fjeld, J G

AU - Hallén, J

AU - Raastad, T

PY - 2010

Y1 - 2010

N2 - The aim of this study was to investigate the effect of a cyclooxygenase (COX)-2 inhibitor on the recovery of muscle function, inflammation, regeneration after, and adaptation to, unaccustomed eccentric exercise. Thirty-three young males and females participated in a double-blind, placebo-controlled experiment. Seventy unilateral, voluntary, maximal eccentric actions with the elbow flexors were performed twice (bouts 1 and 2) with the same arm, separated by 3 weeks. The test group participants were administered 400 mg/day of celecoxib for 9 days after bout 1. After both bouts 1 and 2, concentric and isometric force-generating capacity was immediately reduced (approximately 40-50%), followed by the later appearance of muscle soreness and increased serum creatine kinase levels. Radiolabelled autologous leukocytes (detected by scintigraphy) and monocytes/macrophages (histology) accumulated in the exercised muscles, simultaneously with increased satellite cell activity. These responses were reduced and recovery was faster after bout 2 than 1, demonstrating a repeated-bout effect. No differences between the celecoxib and placebo groups were detected, except for muscle soreness, which was attenuated by celecoxib. In summary, celecoxib, a COX-2 inhibitor, did not detectably affect recovery of muscle function or markers of inflammation and regeneration after unaccustomed eccentric exercise, nor did the drug influence the repeated-bout effect. However, it alleviated muscle soreness.

AB - The aim of this study was to investigate the effect of a cyclooxygenase (COX)-2 inhibitor on the recovery of muscle function, inflammation, regeneration after, and adaptation to, unaccustomed eccentric exercise. Thirty-three young males and females participated in a double-blind, placebo-controlled experiment. Seventy unilateral, voluntary, maximal eccentric actions with the elbow flexors were performed twice (bouts 1 and 2) with the same arm, separated by 3 weeks. The test group participants were administered 400 mg/day of celecoxib for 9 days after bout 1. After both bouts 1 and 2, concentric and isometric force-generating capacity was immediately reduced (approximately 40-50%), followed by the later appearance of muscle soreness and increased serum creatine kinase levels. Radiolabelled autologous leukocytes (detected by scintigraphy) and monocytes/macrophages (histology) accumulated in the exercised muscles, simultaneously with increased satellite cell activity. These responses were reduced and recovery was faster after bout 2 than 1, demonstrating a repeated-bout effect. No differences between the celecoxib and placebo groups were detected, except for muscle soreness, which was attenuated by celecoxib. In summary, celecoxib, a COX-2 inhibitor, did not detectably affect recovery of muscle function or markers of inflammation and regeneration after unaccustomed eccentric exercise, nor did the drug influence the repeated-bout effect. However, it alleviated muscle soreness.

KW - Adaptation, Physiological

KW - Adult

KW - Arm

KW - Cyclooxygenase 2 Inhibitors

KW - Dinoprostone

KW - Double-Blind Method

KW - Exercise

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Isometric Contraction

KW - Leukocytes

KW - Male

KW - Microdialysis

KW - Muscle Contraction

KW - Muscle, Skeletal

KW - Pain

KW - Pyrazoles

KW - Recovery of Function

KW - Satellite Cells, Skeletal Muscle

KW - Sulfonamides

KW - Young Adult

U2 - 10.1111/j.1600-0838.2009.00947.x

DO - 10.1111/j.1600-0838.2009.00947.x

M3 - Journal article

C2 - 19522751

VL - 20

SP - e195-207

JO - Scandinavian Journal of Medicine & Science in Sports

JF - Scandinavian Journal of Medicine & Science in Sports

SN - 0905-7188

IS - 1

ER -

ID: 38364620